OVERVIEW

Join us for this not-to-miss event that brings together community-based providers and esteemed academic oncologists. Together, we will improve patient care and outcomes in hematologic malignancies.

Our mission is clear: To save lives. We're committed to achieving this by exploring cutting-edge treatment options and harnessing medical breakthroughs that will significantly reduce cancer-related fatalities. This includes delving into groundbreaking approaches like CAR T-cell therapy, innovative immunotherapies, and precision-targeted agents.

This activity will help healthcare professionals redefine the standard of care for both newly diagnosed patients and those facing relapsed blood cancers. It will empower them to stay at the forefront of their field by providing them with the latest scientific advancements, inspiring innovative ideas, and addressing the most pressing issues concerning patients afflicted with these diseases.

Together, let's make a real difference in the lives of those battling hematologic malignancies. Join us in shaping the future of hematologic oncology.

TARGET AUDIENCE

This activity is designed for hematologists, medical oncologists, pathologists, fellow and resident trainees, nurse practitioners, physician assistants, nurses, pharmacists, and other healthcare professionals dedicated to treating hematologic cancers.

LEARNING OBJECTIVES

After this activity, participants will be able to:

• Recall the optimal patient selection, timing, and regimens for stem cell transplantation;
• Recognize the optimal sequencing of novel therapeutic options in the care of lymphoma patients with the incorporation of recent advancements in the field;
• Identify available clinical trial options and other approaches to patients with relapsed/refractory disease;
• State the role of existing and emerging targeted agents in leukemias and myeloid neoplasms;
• Discuss how to appropriately sequence treatment in multiple myeloma, from the use of frontline multi-drug combinations to the role of CAR T and bispecific antibodies in relapsed/refractory disease;
• Illustrate how cutting-edge data presented at the 2023 Annual Meeting of the American Society of Hematology can apply to clinical practice;
• Explain how to diagnose and treat common benign hematologic diseases with newly approved therapies;
• Interpret emerging clinical trial data in the context of CAR T-cell therapy for lymphoid malignancies.

ACCREDITATION

Physician Credit
The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity

American Board of Internal Medicine MOC II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Pediatrics MOC Part II Credit
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.5 MOC points in the American Board of Pediatrics's (ABP) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.

For more information please visit the official event page.